Aytu BioPharma to Present at Upcoming September 2025 Conferences

About this update from Aytu Biopharma, Inc.

DENVER, CO / ACCESS Newswire / September 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced management will participate at the following investor conferences: MicroCap Rodeo Fall Conference Date: Thursday, September 25, 2025 Location: New York City Presentation Time: 2:00 p.m. Eastern time Webcast: https://www.webcaster5.com/Webcast/Page/3142/53024 Lytham Partners Fall 2025 Investor Conference Date: Tuesday, September 30, 2025 Location: Virtual Presentation Time: 2:45 p.m. Eastern time Webcast: https://app.webinar.net/K8vDlaelmAd Management will be participating in one-on-one meetings throughout both events. To arrange a meeting with management, please contact Robert Blum of Lytham Partners at [email protected] . About Aytu BioPharma Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), and a line of legacy products, including Karbinal® ER (carbinoxamine maleate), Poly-Vi-Flor® and Tri-Vi-Flor®. To learn more, please visit aytubio.com. Contacts for Investors Ryan Selhorn, Chief Financial Officer Aytu BioPharma, Inc. [email protected] Robert Blum Lytham Partners [email protected] SOURCE: Aytu BioPharma, Inc. View the original press release on ACCESS Newswire

View stock analysis, news, and events for Aytu Biopharma, Inc.